A Study to Assess Safety of Teclistamab in Indian Participants With Relapsed and Refractory Multiple Myeloma

PHASE4RecruitingINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

May 22, 2025

Primary Completion Date

November 3, 2026

Study Completion Date

June 20, 2027

Conditions
Multiple Myeloma
Interventions
DRUG

Teclistamab

Teclistamab will be administered subcutaneously.

Trial Locations (8)

110029

RECRUITING

All India Institute of Medical Sciences, New Delhi

110085

RECRUITING

Rajiv Gandhi Cancer Institute & Research Centre, New Delhi

160012

RECRUITING

Post Graduate Institute of Medical Education And Research PGIMER, Chandigarh

302017

RECRUITING

Bhagwan Mahaveer Cancer Hospital & Research Centre, Jaipur

400012

RECRUITING

Tata Memorial Hospital, Mumbai

440001

RECRUITING

KIMS-Kingsway Hospitals, Nagpur

560054

RECRUITING

M S Ramaiah Medical College and Hospital, Bangalore

700156

RECRUITING

Tata Medical Center, Kolkata

All Listed Sponsors
lead

Johnson & Johnson Private Limited

INDUSTRY

NCT07030517 - A Study to Assess Safety of Teclistamab in Indian Participants With Relapsed and Refractory Multiple Myeloma | Biotech Hunter | Biotech Hunter